CDH17 Antibody (monoclonal) (M01)
- Known as:
- CDH17 Antibody (mab) (M01)
- Catalog number:
- AT1472a
- Category:
- -
- Supplier:
- Abgen
- Gene target:
- CDH17 Antibody (monoclonal) (M01)
Related genes to: CDH17 Antibody (monoclonal) (M01)
- Gene:
- CDH17 NIH gene
- Name:
- cadherin 17
- Previous symbol:
- -
- Synonyms:
- HPT-1, cadherin
- Chromosome:
- 8q22.1
- Locus Type:
- gene with protein product
- Date approved:
- 1997-02-10
- Date modifiied:
- 2016-01-15
- Gene:
- GTF2H2B NIH gene
- Name:
- general transcription factor IIH subunit 2B (pseudogene)
- Previous symbol:
- -
- Synonyms:
- DKFZP686M0199
- Chromosome:
- 5q13.2
- Locus Type:
- pseudogene
- Date approved:
- 2008-07-04
- Date modifiied:
- 2015-11-09
- Gene:
- POLR1A NIH gene
- Name:
- RNA polymerase I subunit A
- Previous symbol:
- -
- Synonyms:
- DKFZP586M0122, FLJ21915, RPO1-4, RPA1
- Chromosome:
- 2p11.2
- Locus Type:
- gene with protein product
- Date approved:
- 2003-04-01
- Date modifiied:
- 2017-06-28
- Gene:
- TDRP NIH gene
- Name:
- testis development related protein
- Previous symbol:
- C8orf42
- Synonyms:
- INM01, TDRP1, TDRP2
- Chromosome:
- 8p23.3
- Locus Type:
- gene with protein product
- Date approved:
- 2005-07-28
- Date modifiied:
- 2015-08-26
Related products to: CDH17 Antibody (monoclonal) (M01)
Related articles to: CDH17 Antibody (monoclonal) (M01)
- Antibody-drug conjugates (ADCs) represent an emerging class of targeted therapeutics with considerable potential in the management of colorectal cancer (CRC). By delivering highly potent cytotoxic agents to cancer cells via specific antibodies, ADCs enable precise tumor targeting while minimizing off-target toxicity. Recent advancements have identified several promising targets for ADC development in CRC, including human epidermal growth factor receptor 2 (HER2), carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), mesenchymal-epithelial transition factor (c-MET), epidermal growth factor receptor (EGFR), cadherin-17 (CDH17), and trophoblast cell surface antigen 2 (Trop-2). Clinical trials have demonstrated encouraging objective response rates and survival benefits with ADCs such as trastuzumab deruxtecan (T-DXd) and disitamab vedotin in patients with advanced CRC. Nonetheless, the clinical application of ADCs faces several challenges, including tumor heterogeneity leading to variable target expression, the emergence of diverse resistance mechanisms that limit long-term efficacy, and manageable but significant safety concerns. Future research should prioritize tumor-selective linker design, novel payload development, bispecific and dual-payload ADC platforms, and rational combination strategies to overcome resistance and further improve the therapeutic index of ADCs in CRC. - Source: PubMed
Publication date: 2026/07/20
Zeng LiliZhu YuanlinZhang KeLiu BinDing Jie - The therapeutic landscape of colorectal cancer (CRC) has evolved with the identification of molecular subtypes, including mismatch repair-deficient/microsatellite instability-high, POLE mutations, RAS/BRAF alterations, and HER2 amplification, enabling use of precision therapies and immune checkpoint inhibitors for selected populations. However, most microsatellite-stable (MSS) tumors remain resistant due to tumor heterogeneity, adaptive resistance, and an immunosuppressive tumor microenvironment (TME). Advances in molecular profiling, spatial biology, and immune characterization have revealed vulnerabilities beyond canonical signaling, facilitating novel strategies such as antibody-drug conjugates (ADCs), bispecific antibodies, DNA damage response (DDR) targeting, TME-directed therapies, cellular therapies, and epigenetic modulation. HER2-directed ADCs, notably trastuzumab deruxtecan, have shown clinically meaningful activity in HER2-positive metastatic CRC, providing proof of concept for ADC-based therapy. Additional targets under investigation include CEACAM5, LGR5, EGFR, HER3, MET, B7-H3, and CDH17. Bispecific antibodies and co-stimulatory agonists are being developed to overcome antigen heterogeneity and pathway redundancy, with the EGFR-MET bispecific antibody amivantamab showing initial clinical efficacy. Moreover, next-generation immune checkpoint inhibitors and multitarget combinations aim to reinvigorate T-cell responses in MSS tumors. Early chimeric antigen receptor T-cell studies targeting CEA and GUCY2C demonstrate feasibility and manageable toxicity, although tumor-intrinsic and TME barriers persist. Emerging strategies increasingly focus on modulating the TME to enhance immune infiltration and effector function, targeting CCR8, TGF-β, adenosine, CSF1R, CXCR1/2, STING, and CD47. DDR and epigenetic therapies offer additional opportunities to sensitize resistant tumors. Integrated, multidimensional biomarker approaches and artificial intelligence-driven interpretation of tumor and TME features are expected to guide personalized therapy, anticipate resistance, and broaden the benefit of targeted and immune-based interventions in CRC. - Source: PubMed
Publication date: 2026/07/16
Bartolini MAlgaze SLenz H-J - Immunohistochemistry (IHC) is essential in diagnostic pathology, but antibody reliability is often limited by insufficient validation and high variability between clones. Conventional validation approaches normally use only few tissues or cell lines which do not reflect tissue and cell type complexity. A high-throughput validation platform based on large-scale tissue microarrays (TMAs) was established to assess antibody specificity across 76 normal tissue types and to evaluate the diagnostic performance in > 15,000 tumours from > 130 entities. Comparative staining with independent antibodies on a full set of normal tissues enables robust detection of cross-reactivity. Comparative staining of critical tumour cohorts under different conditions enables protocol optimization to obtain the best possible sensitivity and specificity for the distinction of different tumour types. Large-scale tumour profiling studies on ≥ 15,000 cancers generated comprehensive datasets refining the diagnostic value of established markers (e.g., CK7/CK20, PLAP) and characterizing the impact of emerging diagnostic targets such as MTAP, CDH16, and CDH17. Furthermore, screening of over 6000 antibodies of previously unknown clinical significance identified various novel diagnostic markers, including CPA1, GAD2, and KDM6A, with high specificity for distinct tumour entities and/or neoplastic transformation. In conclusion, large-scale TMA-based validation improves antibody identification and characterization and provides a robust framework for integrating IHC into digital pathology solutions. - Source: PubMed
Sauter GuidoKluth MartinaTsourlakis Maria ChristinaSauter MarcoDieckert SandraSimon Ronald - Cadherin-17 (CDH17) is a cell-adhesion molecule physiologically expressed along the intestinal epithelial tight junctions. Aberrant overexpression of CDH17 in gastrointestinal (GI) cancers promotes tumor growth and metastasis and is associated with poor patient prognosis. Due to its restricted expression in normal tissues and strong association with malignancy, CDH17 represents an emerging therapeutic target for GI tract cancers. - Source: PubMed
Publication date: 2026/03/12
Yu MingcanMu GuangmaoChen PengBi HongleiZhou FulaiZha ZhengxiaHuang ShengJiang HaoJin YingChen YuantingChiu Mark LZhang Di - Dynein axonemal assembly factors (DNAAF) are essential for the assembly and transport of dynein motor complexes, which are crucial for the movement of cilia. Mutations in genes encoding these proteins often lead to motile ciliopathies called primary ciliary dyskinesia (PCD). In humans, loss-of-function mutations of Cilia and flagella-associated protein 300 (CFAP300, also known as DNAAF17) have been reported to cause PCD. The function of CFAP300 during embryogenesis, however, has not been reported. We carried out functional studies using zebrafish to understand its function during vertebrate development. - Source: PubMed
Publication date: 2026/05/01
Nayak UsharaniSahoo KalyaniBarrodia PraveenSwain Rajeeb K